/

Sociétés

Ad

Non vérifié

Aditxt, Inc.

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté

62 communiqués de presse

Voir tous les communiqués de presse

09/06/2026

Marché du travail

Marché financier

Titres et actions

Biotechnologie

Industrie pharmaceutique

Santé

Oncologie

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

Source

Émetteur

1.00

0

01/06/2026

Biotechnologie

Industrie pharmaceutique

Santé

Oncologie

Marché du travail

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

Source

Émetteur

1.00

0

14/05/2026

Finance

Biotechnologie

Santé

Industrie pharmaceutique

Oncologie

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

Source

Émetteur

1.00

0

20/04/2026

Industrie

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Source

Émetteur

1.00

0

19/03/2026

Science

Biotechnologie

Médecine - Divers

Industrie pharmaceutique

Santé

Oncologie

Marché du travail

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

Source

Émetteur

1.00

0

13/03/2026

Événements

Marché financier

Science

Biotechnologie

Médecine - Divers

Industrie pharmaceutique

Santé

Oncologie

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Source

Émetteur

1.00

0

05/03/2026

Finance

Science

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

Source

Émetteur

1.00

0

18/11/2025

Technique

Santé

Finance

Santé Publique

Associations/Professionnels

Oncologie

Science

Logiciels

Titres et actions

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing

Source

Émetteur

1.00

0

29/10/2025

Santé

Science

Industrie pharmaceutique

Biotechnologie

Finance

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Source

Émetteur

1.00

0

27/10/2025

Santé Publique

Vitrines/Shopping

Santé

Médecine - Divers

Industrie

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0